Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries

INTRODUCTION: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. Hidden access barriers may facilitate financial sustainab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Inotai, András, Tomek, Dominik, Niewada, Maciej, Lorenzovici, László, Kolek, Martin, Weber, Jakub, Kurrat, Anne-Katrin, Kiss, Emese Virág, Kaló, Zoltán
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7291365/
https://ncbi.nlm.nih.gov/pubmed/32581804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00845
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados